Generic Gattex Availability
Last updated on Jun 11, 2025.
Gattex is a brand name of teduglutide, approved by the FDA in the following formulation(s):
GATTEX KIT (teduglutide - powder;subcutaneous)
-
Manufacturer: TAKEDA PHARMS USA
Approval date: December 21, 2012
Strength(s): 5MG/VIAL [RLD]
Is there a generic version of Gattex available?
No. There is currently no therapeutically equivalent version of Gattex available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gattex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Treatment of short bowel syndrome patients with colon-in-continuity
Patent 7,847,061
Issued: December 7, 2010
Inventor(s): Sanguinetti; Elizabeth Lemaire et al.
Assignee(s): NPS Pharmaceuticals, Inc. (Bedminster, NJ)Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Patent expiration dates:
- November 1, 2025✓✓
- November 1, 2025
-
Treatment of short bowel syndrome patients with colon-in-continuity
Patent 7847061*PED
Issued: December 7, 2010
Inventor(s): Sanguinetti; Elizabeth Lemaire et al.
Assignee(s): NPS Pharmaceuticals, Inc. (Bedminster, NJ)Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Patent expiration dates:
- May 1, 2026✓
- May 1, 2026
-
Treatment of short bowel syndrome patients with colon-in-continuity
Patent 9,060,992
Issued: June 23, 2015
Inventor(s): Sanguinetti Elizabeth Lemaire & Marriott Thomas B. & Lopansri Jennifer & Blosch Consuelo Maria
Assignee(s): NPS Pharmaceuticals, Inc.Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Patent expiration dates:
- November 1, 2025✓✓
- November 1, 2025
-
Treatment of short bowel syndrome patients with colon-in-continuity
Patent 9060992*PED
Issued: June 23, 2015
Inventor(s): Sanguinetti Elizabeth Lemaire & Marriott Thomas B. & Lopansri Jennifer & Blosch Consuelo Maria
Assignee(s): NPS Pharmaceuticals, Inc.Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Patent expiration dates:
- May 1, 2026✓
- May 1, 2026
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- May 16, 2026 - TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
More about Gattex (teduglutide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (5)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous GI agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Genotropin
Genotropin is a human growth hormone used to treat growth failure in children and adults who lack ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Norditropin
Norditropin is used to treat growth hormone deficiency (GHD) in adults and children and other ...
Omnitrope
Omnitrope (somatropin) is a form of human growth hormone used to treat adults and children with ...
Humatrope
Humatrope injection (somatropin) is a human growth hormone used to treat growth failure in children ...
Norditropin FlexPro
Norditropin FlexPro is used for adult human growth hormone deficiency, idiopathic short stature ...
Zomacton
Zomacton is used for adult human growth hormone deficiency, idiopathic short stature, pediatric ...
Nutropin AQ
Nutropin AQ (somatropin) is an injectable preparation that may be used to treat children with ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.